Very Short Dual Antiplatelet Therapy after Complex PCI

The 1-month outcomes of dual antiplatelet therapy (DAPT) followed by clopidogrel monotherapy were comparable to 12-month DAPT in patients with both simple and complex PCI. There was no significant interaction between DAPT period and procedure difficulty. 

Doble antiagregación ultra corta luego de una angioplastia compleja

This is a post hoc study of the STOPDAPT-2 that looked at the complex PCI patient subgroup.  

It is important given the uncertain results of clopidogrel monotherapy after a very short DAPT period (1 month), especially in complex PCI. 

The general STOPDAPT-2 randomized patients to 1-month DAPT followed by clopidogrel monotherapy vs. 12-month DAPT in patients undergoing PCI with everolimus eluting stent. 

The substudy defined complex PCI as: 3 target vessels, ≥3 target lesions, ≥3 stents implanted, bifurcation with 2 stent technique, stent length > 60 mm, or chronic total occlusion. With the exception of the left main, these are the traditional criteria which define a complex PCI. 

Primary end point was a composite of cardiovascular death, MI, definite thrombosis, stroke and bleeding (according to TIMI criteria). 


Read also: ACC 2021 | VOYAGER PAD: Usefulness of Rivaroxaban After Peripheral Angioplasty.


Of 3.009 patients included in the general study, 509 met the criteria for complex PCI (16.9%). There was no significant interaction between PCI complexity and 1-month DAPT vs 12-month DAPT in primary end points (complex PCI: 1.67% vs 5.32%, HR 0.30, p=0.04, and simple PCI: 2.5% vs 3.35%, HR 0.75, p=0.23 and for the interaction=0.14).

Accumulated major bleeding was significatively lower in patients receiving 1-month DAPT. This was true regardless PCI complexity. 

Together with the increasing evidence in favor of short DAPT schemes after DES stenting, there is increasing uncertainty over the best monotherapy drug to follow up with. It has been hard to cross data with studies such as the Xience 28 which, unlike the STOPDAPT-2, used aspirin as monotherapy, seeing as it specifically included patients at high risk of bleeding. 


Read also: ACC 2021 | ATLANTIS 4D-CT: Apixaban and Sub-Clinical Thrombosis After TAVR.


Once contemporary DES reach the “class effect”, will come the time to randomize a very short DAPT scheme followed by aspirin vs. a very short DAPT scheme followed by a P2Y12 inhibitor.

Conclusion

Clopidogrel monotherapy after 1-month DAPT is comparable to 12-month DAPT in patients receiving complex PCI. 

Original Title: Very Short Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Patients Who Underwent Complex Percutaneous Coronary Intervention: Insight From the STOPDAPT-2 Trial.

Reference: Ko Yamamoto et al. Circulation: Cardiovascular Interventions. 2021;14:e010384. https://doi.org/10.1161/CIRCINTERVENTIONS.120.010384.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

TCT 2024 | Use of Drug-Coated Balloons for Side Branch Treatment in Provisional Stenting

In some cases, treating coronary bifurcations with provisional stenting requires side branch stenting, which may lead to suboptimal outcomes. Drug-coated balloons (DCBs) have emerged...

TCT 2024 | Use of Artificial Intelligence for Patients with Suspected Coronary Artery Disease

The current approach to chest pain mainly focuses on symptom characteristics, conducting functional tests for ischemia assessment. However, several randomized clinical trials have shown...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...